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Abstract: Trastuzumab (Herceptin), a monoclonal antibody directed against the human 
epidermal growth-factor receptor 2 (HER2), is the poster child for antibody-based targeted 
therapy in breast cancer. Pertuzumab, another humanized monoclonal antibody, binds to a 
different domain of HER2 and prevents the formation of HER2:HER3 dimers, which is the 
most potent heterodimer in the HER family. The combination of trastuzumab and pertuzumab 
has synergistic activity, and is associated with improved clinical outcomes. The US Food and 
Drug Administration (FDA) approved pertuzumab in combination with trastuzumab-based 
chemotherapy originally as first-line therapy for metastatic HER2-positive breast cancer in 
2012, and more recently as neoadjuvant therapy for localized disease in 2013. Pertuzumab is 
the first neoadjuvant drug to receive accelerated approval by the FDA based on pathological 
complete response as the primary end point. In this article, we review the mechanism of action, 
pharmacokinetics, clinical efficacy, safety, and current role of pertuzumab in the management 
of breast cancer, as well as ongoing clinical trials and future directions regarding the utility of 
pertuzumab as a personalized therapeutic option for HER2-positive breast cancer. In the coming 
years, we anticipate increased utilization of neoadjuvant trials for drug development, biomarker 
discovery, and validation, and envision conduct of personalized breast cancer clinics in which 
therapies will be routinely selected based on genetic alterations in the tumor. Regardless of 
the targeted therapy combinations employed based on tumor genomic profile, trastuzumab and 
pertuzumab will likely continue to form the backbone of the personalized regimen for HER2-
positive breast cancer.
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Introduction
Breast cancer is the most common noncutaneous cancer in the US, accounting for 
nearly one in three cancers diagnosed in females. It is estimated that 232,340 women 
in the US will get diagnosed with breast cancer in 2013.1 Human epidermal growth-
factor receptor 2 (HER2) is amplified in approximately one-quarter of breast cancers, 
and HER2-positive tumors represent an aggressive subtype of breast cancer.2
HER2 was discovered in the mid-1980s as a transmembrane tyrosine-kinase 
receptor with a primary sequence very similar to that of the human epidermal growth-
factor 1, and hence was termed HER2.3,4 Its location on chromosomal 17 and the 
185 kD oncogene product of HER2 was coincident with the mouse neu oncogene, 
suggesting that the two genes were identical, and thus the term HER2-neu was coined.2,5 
Subsequently, it was reported that HER2 gene amplification occurs in 20%–30% of 
human breast cancers and HER2 overexpression was a significant and independent Pharmacogenomics and Personalized Medicine 2014:7 submit your manuscript | www.dovepress.com
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predictor of time to relapse and survival among patients with 
breast cancer.6–9
HER2 is a member of the epidermal growth-factor recep-
tor family, all members of which have four distinct domains 
in their molecular structure: an extracellular ligand-binding 
site, a transmembrane region, an intracellular kinase, and an 
intracellular C-terminal tail used for downstream signaling. 
In order to initiate this signaling, a ligand must bind to a 
receptor (HER1, HER3, or HER4), and secondary dimeriza-
tion must occur. Once two family members dimerize, the 
kinase domain of the first receptor becomes active and phos-
phorylates the C-terminal tail of the other, which can then 
recruit scaffold and adaptor proteins for further downstream 
signaling.10 The HER2 receptor is the preferred dimerization 
partner for the other family members, and is unique in that 
it lacks a known ligand, but exists in a conformation that is 
always available to heterodimerize with other family mem-
bers (HER1, HER3, and HER4).
When overexpressed, HER2 can homodimerize and 
initiate ligand-independent constitutive signaling.11 HER3 
receptors lack a kinase domain of their own, and thus 
are incapable of forming homodimers. However, HER3 
can form heterodimers with other HER members, and its 
C-terminal tail contains phosphotyrosine sites that bind with 
key protein domains.12 HER3 can lead to activation of mul-
tiple downstream signaling pathways, making HER2:HER3 
heterodimers extremely potent signaling initiators.12,13 The 
formation of dimers initiates downstream signaling to sev-
eral pathways, particularly the phosphoinositide 3-kinase 
(PI3K) and the mitogen-activated protein kinase pathways.13 
Other members of the growth-factor family, such as fibro-
blast growth-factor receptor and insulin growth-factor 
receptor, can also induce intracellular signaling.14 The net 
consequence of these signaling events is an increase in cel-
lular survival, proliferation, invasiveness, and angiogenesis, 
as outlined in Figure 1.11
While HER2-positive tumors represent an aggressive 
subtype of breast cancer, the prognosis of HER2-positive 
breast cancer has changed dramatically since the introduc-
tion of trastuzumab (Herceptin®), a monoclonal antibody 
against HER2.15 Multiple large randomized clinical trials 
have demonstrated that trastuzumab-based chemotherapy 
is associated with significant improvement in response rate, 
time to disease progression, and overall survival in metastatic 
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Figure 1 Schema outlining the activation of the human epidermal growth-factor receptor 2 pathway and antibody blockade by trastuzumab and pertuzumab.
Abbreviations: HeR, human epidermal growth-factor receptor; FGFR, fibroblast growth-factor receptor; IGFR, insulin-like growth-factor receptor; IV, intravenous; 
Pi3K, phosphoinositide 3-kinase; MeK, mitogen-activated protein kinase kinase; eRK, extracellular signal-regulated kinase; mTOR, mammalian target of rapamycin.Pharmacogenomics and Personalized Medicine 2014:7 submit your manuscript | www.dovepress.com
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breast cancer, as well as improved disease-free survival and 
overall survival in localized breast cancer.16–19
Despite the effectiveness of trastuzumab, a number of 
patients develop primary and secondary resistance. The mecha-
nisms of trastuzumab resistance include incomplete HER2 
blockade from trastuzumab alone, heterodimeric signaling 
from other growth factors, alteration in downstream signaling 
due to oncogene mutations, and loss of HER2 extracellular 
domain.20,21 Several therapeutic strategies to combat this issue 
have emerged. A common approach is to initiate dual HER2 
blockade by combining two different drugs against HER2, such 
as pertuzumab (Perjeta®, Genentech, South San Francisco, 
CA, USA) and lapatinib (Tykerb®, Genentech). Trastuzumab 
emtansine, an antibody drug conjugate, is another drug that 
has demonstrated efficacy in trastuzumab-resistant breast 
cancer.13,22 The clinical success of these therapies highlights 
the fact that HER2 tumors that have become resistant to trastu-
zumab continue to rely on HER2 signaling, and rational target-
ing of the pathway can overcome trastuzumab resistance.
In this review, we focus on pertuzumab and examine its 1) 
mechanism of action and rationale for development, 2) clini-
cal efficacy in various settings, 3) pharmacokinetics, 4) dose 
and regimen, 5) safety and tolerability, and 6) current role in 
the management of breast cancer. We also review ongoing 
clinical trials and future directions regarding the utility of 
pertuzumab as a personalized therapeutic option for HER2-
positive breast cancer.
Pertuzumab
Mechanism of action and rationale  
for development
As demonstrated in Figure 1, trastuzumab and pertu-
zumab bind to different epitopes of HER2. Pertuzumab 
is a humanized monoclonal antibody that binds to HER2 
at subdomain II, which is the extracellular epitope of the 
receptor involved in the dimerization of HER2.23 Pertuzumab 
prevents HER2:HER3 dimer formation and subsequent 
HER3-mediated signaling, whereas trastuzumab binds to 
subdomain IV of the HER2 extracellular domain, prevent-
ing HER2 cleavage.24 The theoretically complementary 
mechanisms of pertuzumab and trastuzumab imply a greater 
efficacy when used together, as they would provide a more 
complete block of downstream signaling. Both of the antibod-
ies share common mechanisms of action, such as antibody-
dependent cellular cytotoxicity.
In preclinical models, the combination of pertuzumab 
with trastuzumab was found to reduce intracellular signaling 
and proliferation in breast cancer cell lines.25,26 In addition, 
the combination induced greater responses in tumor xeno-
grafts than either antibody alone.25 Pertuzumab has been 
also shown to have inhibitory effects in other tumor models, 
including prostate, ovarian, and lung cancer.27–29 The in vitro 
effects for both combination and monotherapies set the stage 
for evaluation of pertuzumab in clinical trials. We focus on 
breast cancer trials in this review.
Clinical efficacy
Metastatic breast cancer
Pertuzumab was initially explored in combination with 
trastuzumab as treatment for HER2-positive metastatic 
breast cancer in patients who had progressed on trastuzumab 
therapy. In a Phase II clinical trial that included advanced 
HER2-positive breast cancer patients with up to three lines 
of prior cytotoxic therapies, or those who had progressed 
during trastuzumab-based therapy as last treatment (n=66), 
the pertuzumab-and-trastuzumab combination induced a 
response rate of 24.2%, with a median progression-free sur-
vival of 5.5 months.30 The combination was well tolerated, 
and adverse events were minimal.
Subsequently, pertuzumab was examined as part of a 
first-line therapeutic combination in the pivotal CLEOPATRA 
(Clinical Evaluation of Pertuzumab and Trastuzumab) trial, 
a randomized, double-blind, placebo-controlled study con-
sisting of 808 patients with HER2-positive metastatic breast 
cancer who were assigned to trastuzumab and docetaxel with 
either placebo or pertuzumab.31,32 The pertuzumab-based com-
bination was associated with a significant increase in median 
progression-free survival from 12.4 to 18.5 months, and 
follow-up analysis indicated a significant increase in overall 
survival, with no significant difference in cardiac toxicity.32,33 
Subgroup analysis of CLEOPATRA indicated that the mag-
nitude of efficacy of dual HER2 blockade with pertuzumab 
and trastuzumab was comparable, irrespective of whether or 
not patients were trastuzumab-naïve.34 Additionally, analysis 
of biomarkers for prognosis or predictive value indicated that 
PIK3CA mutation and HER2/HER3 levels were significantly 
associated with a poor prognosis in both arms.35 A significant 
limitation of this study was the limited number of patients 
who had prior exposure to trastuzumab (about 11%). This 
was primarily due to a lack of use of trastuzumab in the neo-
adjuvant or adjuvant setting at the time of patient enrollment. 
It is expected that ongoing trials, in particular the PHEREXA 
(A Study of a Combination of Trastuzumab and Capecitabine 
with or Without Pertuzumab in Patients with HER2-Positive 
Metastatic Breast Cancer) trial (Table 1), will bring greater 
clarity to the magnitude of benefit in the second-line setting.Pharmacogenomics and Personalized Medicine 2014:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
98
Reynolds et al
Table 1 Key randomized clinical trials evaluating pertuzumab therapy for HeR2-positive breast cancer
Study Setting Regimen Sample size Efficacy
NeoSphere Neoadjuvant A.  Trastuzumab with docetaxel q3 weeks *4 cycles 
 B.  Pertuzumab with docetaxel q3 weeks *4 cycles 
C.    Trastuzumab and pertuzumab with docetaxel  
q3 weeks *4 cycles
Trastuzumab and pertuzumab q3 weeks *4 cycles
417 pCR 
29% in arm A 
vs 24% in arm B 
vs 45.8% in arm C 
vs 16.8% in arm D 
P=0.01 C vs A 
P=0.03 C vs B 
P=0.01 D vs A
TRYPHAeNA Neoadjuvant A.    Trastuzumab, pertuzumab and 5-fluorouracil,  
epirubicin, cyclophosphamide (FeC) q3 weeks  
*3 cycles, followed by trastuzumab, pertuzumab,  
and docetaxel q3 weeks *3 cycles
 B.    5-fluorouracil, epirubicin, and cyclophosphamide  
(FeC) q3 weeks *3 cycles, followed by trastuzumab,  
pertuzumab, and docetaxel q3 weeks *3 cycles
C.    Trastuzumab, pertuzumab, docetaxel, and  
carboplatin chemotherapy q3 weeks *6 cycles
225 pCR in arm A: 56.2% 
in arm B: 54.7% 
in arm C: 63.6% 
(study not powered to 
compare the arms)
APHiNiTY Adjuvant Chemotherapy with trastuzumab, with or without  
pertuzumab
4,800 (planned) Trial ongoing 
(NCT01358877)66
CLeOPATRA Metastatic  
(first-line)
Docetaxel and trastuzumab, with or without  
pertuzumab
808 Median DFS: 18.5 vs  
12.4 months (P,0.05) 
HR 0.62, 95% Ci 0.51–0.75; 
P,0.001 
Median OS: 37.6 months in 
placebo arm, median OS not 
reached in pertuzumab arm 
HR 0.66, 95% Ci 0.52–0.84; 
P=0.0008)
MARiANNe Metastatic  
(first-line)
A.  T-DM1 and placebo 
 B.  T-DM1 and pertuzumab 
C.  Trastuzumab and taxane
1,095 (planned) Trial ongoing 
(NCT01120184)67
PHeReXA Metastatic  
(second-line)
Capecitabine and trastuzumab, with or without  
pertuzumab
450 (planned) Trial ongoing 
(NCT01026142)68
Abbreviations: HeR, human epidermal growth-factor receptor; pCR, pathological complete response; DFS, disease-free survival; OS, overall survival; HR, hazard ratio; Ci, 
confidence interval; vs, versus; q3 weeks, every 3 weeks; NeoSphere, Neoadjuvant Study of Per  tuzumab and Herceptin in an Early Regimen Evaluation; TRYPHAENA, Neoadjuvant 
Pertuzumab and Trastuzumab Concurrent or Sequential with an Anthracycline-Containing or Con  current with an Anthracycline-Free Standard Regimen: A Randomized Phase 
ii Study; APHiNiTY, Adjuvant Pertuzumab and Herceptin in initial Therapy of Breast Cancer; CLeOPATRA, Clinical evaluation of Pertuzumab and Trastuzumab; MARiANNe, 
A Study of Trastuzumab emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo versus Trastuzumab [Herceptin] Plus a Taxane in Patients with Metastatic Breast Cancer; 
PHeReXA, A Study of a Combination of Trastuzumab and Capecitabine with or without Pertuzumab in Patients with HeR2-Positive Metastatic Breast Cancer.
Pertuzumab, like other HER2-directed therapies, has minimal 
efficacy in HER2-negative breast cancer. In a Phase II randomized 
trial among women with metastatic HER2-negative breast cancer 
(n=79), pertuzumab was found to have limited efficacy, with only 
7.7% of patients achieving either a partial response or greater than 
6 months of stable disease.36 In another trial among women with 
trastuzumab-resistant metastatic breast cancer, patients (n=29) 
received pertuzumab monotherapy, and at the time of progression, 
17 received dual blockade with pertuzumab and trastuzumab. The 
dual-combination therapy arm had significantly higher progression-
free survival compared to monotherapy (17.4 weeks versus 7.1 
weeks), highlighting the clinical effectiveness of dual blockade.37
Neoadjuvant trials
Neoadjuvant (preoperative) therapy refers to administration 
of systemic therapy before surgery. Potential advantages 
of neoadjuvant over adjuvant therapy include downstaging 
of tumors to increase the likelihood of breast-conserving 
therapy, early initiation of systemic therapy to prevent distant 
metastasis, and the ability to assess in vivo tumor response to 
therapy by assessing pathological complete response (pCR), 
a surrogate marker of survival.38 Traditionally, single-agent 
trastuzumab-based neoadjuvant therapy has been considered 
the standard of care. However, a number of clinical trials have 
evaluated the clinical utility of dual HER2-directed therapy, 
and the resulting data suggest targeting multiple mechanisms 
may increase efficacy. A recent meta-analysis reported that 
dual HER2 blockade compared to trastuzumab alone did 
not improve breast-conserving surgery rate (relative risk 
[RR] 1.03, P=0.84), but significantly increased rates of pCR 
overall (RR 1.39, P,0.00001), with no increase in grade 3/4 
toxicity (RR 1.13, P=0.16).39 Higher pCR was associated with Pharmacogenomics and Personalized Medicine 2014:7 submit your manuscript | www.dovepress.com
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improved disease-free survival as well as overall survival, 
which is further evidence of pCR as a surrogate end point 
for survival in HER2-positive breast cancers.40
Two pertuzumab-containing neoadjuvant regimens merit 
particular attention. NeoSphere (Neoadjuvant Study of Per-
tuzumab and Herceptin in an Early Regimen Evaluation) 
enrolled 417 breast cancer patients with locally advanced, 
inflammatory, or early HER2-positive breast cancers .2 cm 
to pertuzumab, trastuzumab, both with docetaxel, or both 
without docetaxel.41 The schema of the NeoSphere trial is 
outlined in Figure 2. Patients treated with dual HER2 block-
ade plus docetaxel had significantly improved pCR at 45.8%, 
compared with trastuzumab plus docetaxel, with pCR of 
29%. Of note, those treated with dual HER2 therapy without 
chemotherapy had a pCR of 16.8%, suggesting a subset of 
breast cancers might respond to dual HER2 blockade with-
out chemotherapy. There were no significant differences in 
tolerability between the arms that contained chemotherapy; 
however, antibody-only therapy had significantly fewer seri-
ous adverse events. TRYPHAENA (Neoadjuvant Pertuzumab 
and Trastuzumab Concurrent or Sequential with an Anthracy-
cline-Containing or Concurrent with an Anthracycline-Free 
Standard Regimen: A Randomized Phase II Study), another 
Phase II clinical trial, was conducted in the neoadjuvant 
setting to evaluate the toxicity of HER2 blockade with the 
chemotherapeutic agents anthracycline and carboplatin.42 
The study enrolled 225 patients with locally advanced and 
inflammatory HER2-positive breast cancer. Pertuzumab and 
trastuzumab were administered, either sequentially or concur-
rently with an anthracycline-containing regimen or concur-
rently with an anthracycline-free regimen, to determine the 
safety profile. Regardless of the chemotherapy chosen, the 
combination of pertuzumab with trastuzumab in the neo-
adjuvant setting resulted in high pCR rates (45.3%−66%). 
These two neoadjuvant trials led to an accelerated approval 
of pertuzumab by the US Food and Drug Administration 
(FDA) as a neoadjuvant therapy (see the “Current role in 
management of breast cancer” section).
Adjuvant trials
While trastuzumab has an established role in the adjuvant 
therapy of HER2-positive patients, the role of adjuvant per-
tuzumab is not clear.16,43 The ongoing APHINITY   (Adjuvant 
Pertuzumab and Herceptin in Initial Therapy of Breast Cancer) 
trial will evaluate the benefit of dual blockade in adjuvant 
therapy with trastuzumab and chemotherapy in patients who 
have undergone resection for HER2-positive breast cancer.44 
A schema of the APHINITY trial design is shown in Figure 3. 
The primary outcome is disease free survival among the tar-
geted 3,806 participants, with secondary outcomes including 
overall survival, quality of life, and safety, including cardiac 
safety. The initial results from this trial are anticipated in 2016 
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Figure 2 Schema of the NeoSphere clinical trial comparing various neoadjuvant HeR2-directed therapies for localized HeR2-positive breast cancer.
Abbreviations: HeR, human epidermal growth-factor receptor; pCR, pathological complete response.Pharmacogenomics and Personalized Medicine 2014:7 submit your manuscript | www.dovepress.com
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and will be pivotal in clarifying the role and long term safety 
of pertuzumab in the adjuvant setting.
Review of pharmacokinetics
Pertuzumab shows a pharmacokinetic profile similar to most 
immunoglobulin G antibodies, including trastuzumab. It has 
a mean half-life of about 3 weeks, and is well tolerated up to 
a dose of 25 mg/kg.45 Some degree of individual variability 
and linear pharmacokinetics has been observed. Current 
dosing recommendations consist of infusing a loading dose 
of 840 mg and administering 420 mg every 3 weeks. The 
pharmacokinetics are affected only slightly by body weight 
or body surface area and are unaltered in the elderly, and 
thus dose adjustment is not required.46
Safety and tolerability
Adverse effects
In general, pertuzumab is safe and well tolerated; how-
ever, it is recommended to observe patients for a period 
of 60 minutes after the first infusion and 30 minutes after 
subsequent infusions. While less than 1% of the infusion 
reactions in the CLEOPATRA trial were grade 3–4, if one 
of these serious reactions does occur, the infusion should 
be interrupted and appropriate rescue therapy administered. 
The patient should be monitored closely until they return to 
baseline, and providers should consider permanent discon-
tinuation of pertuzumab therapy. For patients randomized to 
the pertuzumab-based regimen within the trial, mild day 1 
infusion reactions occurred in up to 13.0% in the pertuzumab 
treated group versus 9.8% in control group. Overall, the most 
common (.30%) adverse reactions were diarrhea, alopecia, 
neutropenia, nausea, fatigue, rash, and peripheral neuropathy, 
while the most common grade 3–4 adverse reactions (2%) 
were febrile neutropenia, neutropenia, leukopenia, diarrhea, 
peripheral neuropathy, anemia, asthenia, and fatigue.47 More 
serious adverse reactions are rare, and include anaphylactic 
reactions, drop in left ventricular ejection fraction (EF), 
and negative effects on fetal development in utero. Adverse 
reactions resulted in discontinuation of therapy in 6.1% 
of the patients in the pertuzumab arm versus 5.3% in con-
trol arm.32
Pregnancy
Pertuzumab use is not recommended for women who are 
pregnant or breastfeeding. It is imperative to verify status 
of pregnancy prior to starting pertuzumab, and contracep-
tion is recommended during and for 6 months after therapy. 
Preclinical studies in animals have resulted in oligohydram-
nios, delayed renal development, and even fetal death. If per-
tuzumab is unknowingly administered during pregnancy, or if 
a patient becomes pregnant while receiving pertuzumab, that 
information should be immediately reported to the Genentech 
Adverse Event Line. In addition, those women should be 
persuaded to enroll in the MotHER Pregnancy Registry.48
immunogenicity
In general, monoclonal antibodies have a potential for 
immunogenic responses in the form of antibody production. 
Anti-pertuzumab antibodies have been noted in a small pro-
portion of patients; however, the pharmacokinetic impact or 
clinical significance of these antibodies is not known. In the 
CLEOPATRA trial, approximately 2.8% of patients in the 
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Figure 3 Schema of the APHINITY clinical trial evaluating efficacy of adjuvant pertuzumab based therapy in localized HER2-positive breast cancer.
Notes: aTrastuzumab 6 mg/kg iv q3 weeks, pertuzumab 420 mg iv q3 weeks; beither anthracycline-based regimen with a taxane, or Taxotere with carboplatin; cHeR2 therapy 
for 1 year (52 weeks).
Abbreviations: HeR, human epidermal growth-factor receptor; iv, intravenous; q3 weeks, every 3 weeks; APHiNiTY, Adjuvant Pertuzumab and Herceptin in initial Therapy 
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pertuzumab group and 6.2% of patients in the placebo-treated 
group tested positive for anti-pertuzumab antibodies.32 The 
presence of pertuzumab antibodies despite no pertuzumab 
being administered is not well understood, though it is 
possible the assay is detecting antibodies to trastuzumab. 
The presence of antibodies did not correlate with infusion 
reactions.
Cardiac toxicity
Cardiac toxicity is associated with anti-HER2 therapies, 
particularly trastuzumab, which occurs due to a toxic 
effect on cardiac myocytes; however, pertuzumab appears 
to have lower cardiac toxicity than trastuzumab.49,50 In the 
CLEOPATRA study, left ventricular dysfunction was docu-
mented in 4.4% of patients in the pertuzumab-treated group 
versus 8.3% of patients in the placebo group. Grade 3 left 
ventricular systolic dysfunction occurred in 1.2% of patients 
in the pertuzumab treated group versus 2.8% of patients in 
the placebo group.32 It is thought that patients with prior 
anthracycline use or chest radiation may be at higher risk 
for decline of EF; therefore, it is recommended that patients 
should have echocardiography at baseline and every 3 months 
while on pertuzumab therapy. If a patient experiences a drop 
in EF to ,40%, or EF of 40%–45% with a 10% absolute 
decrease from baseline, the provider should hold pertuzumab 
(and trastuzumab) for at least 3 weeks. Therapy can be reini-
tiated if the left ventricular EF on repeat echocardiography 
at 3 weeks recovers to .45%, or 40%–45% if associated 
with a less than 10% absolute decrease from baseline. If 
recovery is not demonstrated, discontinuation of therapy 
should be considered. It is also important to note that clini-
cal trials to date have not included patients with a baseline 
EF of ,50%, history of congestive heart failure, drop in 
EF to ,50% on trastuzumab, or conditions that impair LV 
function (hypertension, myocardial infarction, arrhythmia), 
and thus the safety of pertuzumab-based therapy for such 
patients is not known.
Current role in management  
of breast cancer
Pertuzumab (Perjeta) was FDA-approved in 2012, with a pri-
mary indication of first-line use in metastatic breast cancer in 
combination with trastuzumab and docetaxel. This approval 
was based primarily on results from the CLEOPATRA study. 
In September 2013, based on the results from neoadjuvant 
trials (Table 1), the FDA granted accelerated approval to neo-
adjuvant pertuzumab in combination with trastuzumab-based 
chemotherapy for patients with localized, locally advanced, 
inflammatory, or early (.2 cm tumor size or lymph node-
positive) HER2-positive breast cancer.51
The pertuzumab-based regimens, as per the current FDA 
prescribing label, are listed in Table 2.52 The recommended 
loading dose of pertuzumab is 840 mg given as an intravenous 
infusion over 60 minutes. Subsequent doses are 420 mg given 
Table 2 Pertuzumab-based chemotherapy regimens as per the 
US  Food  and  Drug  Administration  prescribing  label  (updated 
September 2013)
Regimen Dose and frequency
Neoadjuvant regimen
FeC-THP* 5-Flurouracil 600 mg/m2, concurrent with 
epirubicin 90 mg/m2, concurrent with 
cyclophosphamide 600 mg/m2, concurrent with 
every 3 weeks *3 cycles, followed by Docetaxel  
75 mg/m2, concurrent with 
pertuzumab loading dose of 840 mg, followed by  
420 mg, concurrent with 
trastuzumab 8 mg/kg loading dose, and then 6 mg/kg 
every 3 weeks *4 cycles, followed by 
trastuzumab alone 6 mg/kg every 3 weeks, to 
complete a total of 52 weeks of treatment
FeCHP-THP* 5-Flurouracil 600 mg/m2, concurrent with 
epirubicin 90 mg/m2, concurrent with 
cyclophosphamide 600 mg/m2, concurrent with 
pertuzumab loading dose of 840 mg, followed by  
420 mg, concurrent with 
trastuzumab 8 mg/kg loading dose, and then 6 mg/kg 
every three weeks *3 cycles, followed by Docetaxel  
75 mg/m2, concurrent with 
pertuzumab loading dose of 840 mg, followed by  
420 mg, concurrent with 
trastuzumab 8 mg/kg loading dose, and then 6 mg/kg 
every 3 weeks *4 cycles, followed by 
trastuzumab alone 6 mg/kg every 3 weeks, to 
complete a total of 52 weeks of treatment
P-TCH Pertuzumab loading dose of 840 mg, followed by  
420 mg, concurrent with 
trastuzumab 8 mg/kg loading dose, and then 6 mg/kg, 
concurrent with 
docetaxel 75 mg/ m2, concurrent with 
carboplatin AUC 6 
every three weeks *6 cycles, followed by 
trastuzumab alone 2 mg/kg weekly or 6 mg/kg every  
3 weeks, to complete a total of 52 weeks of 
treatment
Metastatic regimen
Pertuzumab and  
trastuzumab
Trastuzumab 8 mg/kg loading dose, followed by  
6 mg/kg, concurrent with 
pertuzumab loading dose of 840 mg, followed by  
420 mg, concurrent with 
docetaxel 75–100 mg/m2 (at least 6 cycles) 
every 3 weeks
Notes: *in the US, an Adriamycin–cyclophosphamide (AC) regimen is frequently 
used instead of an FEC regimen. However, there are no safety or efficacy data 
regarding the combination of an AC regimen with pertuzumab.
Abbreviation: AUC, area under curve.Pharmacogenomics and Personalized Medicine 2014:7 submit your manuscript | www.dovepress.com
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as an intravenous infusion over 30–60 minutes, and there are 
no recommended dose reductions.47 It is important to note that 
the safety of neoadjuvant pertuzumab for more than six cycles 
in early breast cancer, or as part of a doxorubicin-containing 
regimen, has not been established. Also, cost issues need to 
be balanced against potential benefits.53
Pertuzumab is the first neoadjuvant drug to receive 
accelerated approved by the FDA based on pCR as the pri-
mary end point. The full approval is contingent on the final 
results of APHINITY, the confirmatory study detailed in 
both Figure 3 and in the “Neoadjuvant trials” section of this 
review. The FDA reserves the right to withdraw approval 
for pertuzumab in the neoadjuvant setting if the results of 
APHINITY are negative. This accelerated process represents 
a paradigm shift in FDA approval, and may replace the long-
standing model of drug development in oncology, which 
is protracted, inefficient, and costly. The neoadjuvant trial 
model offers a platform for rapid and efficient triage of drugs, 
as well as biomarker discovery to facilitate development of 
personalized therapy for breast cancer, and is reviewed in 
the next section.
Future directions
In the current era of targeted and personalized therapeu-
tics in cancer, the classic approach of “one size fits all” 
cancer therapy is increasingly becoming obsolete. Since 
the remarkable successes of trastuzumab for HER2 breast 
cancer, there have been great strides in the development 
of targeted therapies. The field of breast cancer, particu-
larly HER2-positive breast cancer, is now expanding with 
the addition of multiple active targeted therapies. In the 
future, we anticipate the routine use of genomics to identify 
biomarkers and accordingly select patients who will opti-
mally benefit from particular anti-HER2 agents or therapy 
combinations. In addition, we expect increased utilization 
of neoadjuvant trials for drug development, biomarker 
discovery, and validation. These issues are discussed in 
the following sections.
Role of biomarkers and genome sequencing
Genome sequencing of tumor specimens is gaining increased 
traction in routine clinical practice.54 We anticipate that over 
the coming years, next-generation sequencing will be utilized 
routinely for discovery of genomic alterations in tumors. 
While promising, it should be noted that routine tumor 
sequencing does pose a number of challenges. Besides the 
ethical and regulatory issues, tumor sequencing generates an 
enormous amount of data, with the consequent challenge of 
unscrambling “driver” mutations from “passenger” mutations. 
As we move in the genomic era, it will be particularly impor-
tant to focus on driver mutations that are “actionable”, ie, 
modulated by a targeted therapy, and design biomarker-
stratified clinical trials appropriately.55
For HER2-positive breast cancer, it will be particularly 
important to identify oncogene mutations in the PI3K 
pathway, not only because PI3K mutations predict poor 
therapeutic response to trastuzumab and pertuzumab but 
also that tumors harboring a PI3K mutation can be subject 
to inhibition by PI3K inhibitors.56,57 Similarly, overexpres-
sion of HER3 is a biomarker that is associated with poor 
prognosis and lower response to HER2 therapies, including 
pertuzumab, and combination with anti-HER3 therapies 
would be potentially important for this subgroup.58–60 
Obviously, these biomarker-driven hypotheses will need to 
be investigated and validated before they can be incorporated 
into clinical practice. We anticipate that neoadjuvant trials 
will increasingly be utilized for this purpose, as discussed 
in the next section.
Role of neoadjuvant trials
Neoadjuvant trials utilizing pCR, a validated surrogate end 
point for survival, as the primary end point provide an attrac-
tive platform for rapid triage of drug efficacy, biomarker iden-
tification, and validation.61 The FDA approval of neoadjuvant 
pertuzumab based on pCR as the primary end point serves 
as a validation of this drug-development model.62 Over the 
coming years, there will be a marked increase in the utiliza-
tion of neoadjuvant trials in breast clinics, not only for drug 
approval of novel agents but also to compare different combi-
nations for synergistic HER2 blockade, to identify predictive 
biomarkers for individual therapies, and to determine the 
optimal sequencing of HER2-blocking agents.63 Neoadjuvant 
trials testing combination therapies that have the potential of 
overcoming treatment resistance by inhibiting compensatory 
cross talk between pathways, such as the combination of 
HER2 directed therapies with PI3K inhibitors, or anti-HER3 
therapies, will be particularly valuable. Similarly, for HER2-
positive tumors that are also hormone receptor-positive, it 
would be important to incorporate therapies that also target 
the estrogen receptor, since the combination of neoadjuvant 
endocrine and HER2 therapy can have additive therapeutic 
efficacy.64 Safety is a key issue for neoadjuvant trials, and it 
will be important to consider carefully the amount of safety 
data present, avoid drugs with significant overlapping tox-
icities, and utilize innovative protocol development like the 
adaptive study design.65Pharmacogenomics and Personalized Medicine 2014:7 submit your manuscript | www.dovepress.com
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In the coming years, we envision personalized breast 
  cancer clinics in which therapies will be routinely selected 
based on genetic alterations in tumors. A potential example of 
such a personalized therapy selection for HER2-positive breast 
cancer is outlined in Figure 4. Trastuzumab and pertuzumab 
will likely form the backbone of the various targeted therapy 
combinations employed in the personalized regimen.
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